137334-69-1

Usage

Classification

brominated aromatic compound
It is an aromatic compound with a bromine atom attached to the benzene ring.

Structure

benzene ring with two methoxymethyl groups and a bromine atom at the 1 and 3 positions
The benzene ring has two methoxymethyl (-OCH2OCH3) groups and a bromine atom attached to it, specifically at the 1st and 3rd carbon positions.

Usage

organic synthesis building block
It serves as a starting material for the preparation of various derivatives in organic chemistry.

Application

reagent for introducing bromine functional group
It can be used in chemical reactions to add a bromine atom to other molecules.

Flammability

flammable
The compound can easily catch fire and burn, so it should be handled with care.

Hazards

potential for skin, eye, and respiratory irritation
Exposure to the compound may cause irritation to the skin, eyes, and respiratory system, so proper safety measures should be taken during handling and use.

Upstream product

• 51760-22-6 5-bromo-1,3-dihydroxymethylbenzene 
• 74-88-4 methyl iodide 

Downstream Products

• 137334-70-4 3,5-bis(methoxymethyl)benzaldehyde 
• 137334-72-6 2,7,12-tris<<3,5-bis(chloromethyl)phenyl>methyl>-10,15-dihydro-3,8,13-trimethoxy-5H-tribenzocyclononene racemate 
• 137334-71-5 2,7,12-tris<<3,5-bis(methoxymethyl)phenyl>methyl>-10,15-dihydro-3,8,13-trimthoxy-5H-tribenzocyclononene racemate 
• 137334-67-9 1,13,14,21,22,34-hexahydro-30,36,48-trimethoxy-13,21,44-tris<(4-methylphenyl)sulfonyl>-6H,12H,20H,28H-2,5-etheno-9,25-<(methanimino)methano>3,32:17,37-dimethano-7,11:15,19:23,27:29,33-tetrametheno-13,21-benzodiazacyclohexatriacontine racemate 

Relevant academic research and scientific papers

Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl or pyrrolyl, or cycloalkenyl R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; and Z is optionally substituted aryl or heteroaryl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.

2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; R6 is H, alkyl, hydroxyalkyl or —CH2F; R7, R8 and R9 are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or —CF3; and Z is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.

Cis-imidazolines

The present invention provides compounds according to formula I and formula II and pharmaceutically acceptable salts and esters thereof, having the designations provided herein and which inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity

Rigidly Hollow Hosts That Encapsulate Small Molecules

New chiral host systems 1 and 2 possessing C3 symmetry have been designed and synthesized.Molecular models of 1 and 2 indicate they contain small enforced cavities and three portals complementary to small molecules.The crystal structure of 1*2CH3CN shows